Genmab — September 2018
-
kunne der være noget på vej? kursen er lidt underlig…
-
Den har været underlig de sidste mange dage, så det tror jeg ikke man skal lægge ret meget vægt på.
-
Håber dog at jeg tager fejl
-
...soon...:-)
-
New Phase 2 trial: Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia https://clinicaltrials.gov/ct2/show/NCT03679624?term=daratumumab+OR+ofatumumab+OR+tisotumab&lupd_s=09%2F20%2F2018&rank=1
-
Molecular Templates and Takeda to Take on Multiple Myeloma in Deal Worth up to $632 Million https://www.biospace.com/article/am6a-molecular-templates-and-takeda-to-take-on-multiple-myeloma-in-deal-worth-up-to-632-million/
-
The increasing knowledge of disease biology allowed to recognise new potential therapeutic targets, such as CD38 that is expressed on the surface of almost half of WM malignant cells.133 Daratumumab, a monoclonal antibody against CD38, approved for the treatment of multiple myeloma, is a promising agent for the treatment of WM
-
-
Livet er langt..lykken er kort...så lad os se om det holder.
-
production failure for Yescarta or Kymriah (in lymphoma)? https://twitter.com/DrMiguelPerales/status/1042592569664983042
-
auktionen ser altså underlig ud
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind